- Home
- Publications
- Publication Search
- Publication Details
Title
Evolving Role of Immunotherapy in Advanced Biliary Tract Cancers
Authors
Keywords
-
Journal
Cancers
Volume 14, Issue 7, Pages 1748
Publisher
MDPI AG
Online
2022-03-30
DOI
10.3390/cancers14071748
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- A phase 3 randomized, double-blind, placebo-controlled study of durvalumab in combination with gemcitabine plus cisplatin (GemCis) in patients (pts) with advanced biliary tract cancer (BTC): TOPAZ-1.
- (2022) Do-Youn Oh et al. JOURNAL OF CLINICAL ONCOLOGY
- Crizotinib in patients with tumors harboring ALK or ROS1 rearrangements in the NCI-MATCH trial
- (2022) A. S. Mansfield et al. npj Precision Oncology
- Targeting HER2 (ERBB2) mutation-positive advanced biliary tract cancers with neratinib: Results from the phase II SUMMIT ‘basket’ trial.
- (2021) James J. Harding et al. JOURNAL OF CLINICAL ONCOLOGY
- Lenvatinib plus pembrolizumab for patients with previously treated biliary tract cancers in the multicohort phase II LEAP-005 study.
- (2021) Luis Villanueva et al. JOURNAL OF CLINICAL ONCOLOGY
- Pitfalls, challenges, and updates in adjuvant systemic treatment for resected biliary tract cancer
- (2021) Alessandro Rizzo et al. Expert Review of Gastroenterology & Hepatology
- Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): a phase 3, open-label, randomised, controlled trial
- (2021) Angela Lamarca et al. LANCET ONCOLOGY
- 47P Derazantinib for patients with intrahepatic cholangiocarcinoma harboring FGFR2 fusions/rearrangements: Primary results from the phase II study FIDES-01
- (2021) M. Droz Dit Busset et al. ANNALS OF ONCOLOGY
- LBA10 Nal-IRI with 5-fluorouracil (5-FU) and leucovorin or gemcitabine plus cisplatin in advanced biliary tract cancer: Final results of the NIFE-trial (AIO-YMO HEP-0315), a randomized phase II study of the AIO biliary tract cancer group
- (2021) L. Perkhofer et al. ANNALS OF ONCOLOGY
- Camrelizumab plus oxaliplatin‐based chemotherapy as first‐line therapy for advanced biliary tract cancer: A multicenter, phase 2 trial
- (2021) Xinni Chen et al. INTERNATIONAL JOURNAL OF CANCER
- Toripalimab with chemotherapy as first-line treatment for advanced biliary tract tumors: Update analytic results of an open-label phase II clinical study (JS001-ZS-BC001).
- (2021) Wei Li et al. JOURNAL OF CLINICAL ONCOLOGY
- Gemox chemotherapy in combination with anti-PD1 antibody toripalimab and lenvatinib as first-line treatment for advanced intrahepatic cholangiocarcinoma: A phase 2 clinical trial.
- (2021) Zhou Jian et al. JOURNAL OF CLINICAL ONCOLOGY
- Pertuzumab and trastuzumab for HER2-positive, metastatic biliary tract cancer (MyPathway): a multicentre, open-label, phase 2a, multiple basket study
- (2021) Milind Javle et al. LANCET ONCOLOGY
- Final Overall Survival Efficacy Results of Ivosidenib for Patients With Advanced Cholangiocarcinoma With IDH1 Mutation
- (2021) Andrew X. Zhu et al. JAMA Oncology
- Modified FOLFIRINOX Versus CISGEM Chemotherapy for Patients With Advanced Biliary Tract Cancer (PRODIGE 38 AMEBICA): A Randomized Phase II Study
- (2021) Jean marc Phelip et al. JOURNAL OF CLINICAL ONCOLOGY
- Infigratinib (BGJ398) in previously treated patients with advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements: mature results from a multicentre, open-label, single-arm, phase 2 study
- (2021) Milind Javle et al. Lancet Gastroenterology & Hepatology
- Current and emerging therapies for advanced biliary tract cancers
- (2021) Audrey E Kam et al. Lancet Gastroenterology & Hepatology
- Ramucirumab (RAM) or merestinib (MER) or placebo (PL) plus gemcitabine (GEM) and cisplatin (CIS) as first-line treatment for advanced or metastatic biliary tract cancer (BTC): A randomized, double-blind, phase II study.
- (2020) Juan W. Valle et al. JOURNAL OF CLINICAL ONCOLOGY
- Second-line therapies in advanced biliary tract cancers
- (2020) Sri Harsha Tella et al. LANCET ONCOLOGY
- Regorafenib after failure of gemcitabine and platinum-based chemotherapy for locally advanced/metastatic biliary tumors: a randomized, double-blind, phase 2 trial – REACHIN
- (2020) A. Demols et al. ANNALS OF ONCOLOGY
- Efficacy and safety of pembrolizumab for the treatment of advanced biliary cancer: Results from the KEYNOTE-158 and KEYNOTE-028 studies
- (2020) Sarina A. Piha-Paul et al. INTERNATIONAL JOURNAL OF CANCER
- A multicenter randomized phase II study of nivolumab in combination with gemcitabine/cisplatin or ipilimumab as first-line therapy for patients with advanced unresectable biliary tract cancer (BilT-01).
- (2020) Vaibhav Sahai et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II study assessing tolerability, efficacy, and biomarkers for durvalumab (D) ± tremelimumab (T) and gemcitabine/cisplatin (GemCis) in chemo-naïve advanced biliary tract cancer (aBTC).
- (2020) Do-Youn Oh et al. JOURNAL OF CLINICAL ONCOLOGY
- Final results from the phase I study expansion cohort of the selective FGFR inhibitor Debio 1,347 in patients with solid tumors harboring an FGFR gene fusion.
- (2020) James M. Cleary et al. JOURNAL OF CLINICAL ONCOLOGY
- Molecular targeted therapies: Ready for “prime time” in biliary tract cancer
- (2020) Angela Lamarca et al. JOURNAL OF HEPATOLOGY
- Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study
- (2020) Ghassan K Abou-Alfa et al. LANCET ONCOLOGY
- Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study
- (2020) Ghassan K Abou-Alfa et al. LANCET ONCOLOGY
- A Phase 2 Multi-institutional Study of Nivolumab for Patients With Advanced Refractory Biliary Tract Cancer
- (2020) Richard D. Kim et al. JAMA Oncology
- Phase I study of bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in patients with pretreated biliary tract cancer
- (2020) Changhoon Yoo et al. Journal for ImmunoTherapy of Cancer
- Cholangiocarcinoma 2020: the next horizon in mechanisms and management
- (2020) Jesus M. Banales et al. Nature Reviews Gastroenterology & Hepatology
- High PD-L1 expression is associated with therapeutic response to pembrolizumab in patients with advanced biliary tract cancer
- (2020) Soomin Ahn et al. Scientific Reports
- Evaluation of Combination Nivolumab and Ipilimumab Immunotherapy in Patients With Advanced Biliary Tract Cancers
- (2020) Oliver Klein et al. JAMA Oncology
- Efficacy and biomarker analysis of nivolumab plus gemcitabine and cisplatin in patients with unresectable or metastatic biliary tract cancers: results from a phase II study
- (2020) Kaichao Feng et al. Journal for ImmunoTherapy of Cancer
- Combined PARP Inhibition and Immune Checkpoint Therapy in Solid Tumors
- (2020) Florent Peyraud et al. Cancers
- Dabrafenib plus trametinib in patients with BRAFV600E-mutated biliary tract cancer (ROAR): a phase 2, open-label, single-arm, multicentre basket trial
- (2020) Vivek Subbiah et al. LANCET ONCOLOGY
- A review of systemic therapy in biliary tract carcinoma
- (2020) Holger Jansen et al. Journal of Gastrointestinal Oncology
- Phase 2 study of copanlisib in combination with gemcitabine and cisplatin in advanced biliary tract cancers
- (2020) Elaine S. Tan et al. CANCER
- Triplet combination of durvalumab, tremelimumab, and paclitaxel in biliary tract carcinomas: Safety run-in results of the randomized IMMUNOBIL PRODIGE 57 phase II trial
- (2020) Alice Boilève et al. EUROPEAN JOURNAL OF CANCER
- A Phase Ib Study of NUC ‐1031 in Combination with Cisplatin for the First‐Line Treatment of Patients with Advanced Biliary Tract Cancer ( ABC ‐08)
- (2020) Mairéad G. McNamara et al. ONCOLOGIST
- Recent advances of immunotherapy for biliary tract cancer
- (2020) Alessandro Rizzo et al. Expert Review of Gastroenterology & Hepatology
- A Perspective on Cell Therapy and Cancer Vaccine in Biliary Tract Cancers (BTCs)
- (2020) Shuting Han et al. Cancers
- The Tumor Microenvironment and Immune Milieu of Cholangiocarcinoma
- (2019) Luca Fabris et al. LIVER INTERNATIONAL
- Evaluation of safety and tolerability of durvalumab (D) with or without tremelimumab (T) in patients (pts) with biliary tract cancer (BTC).
- (2019) Tatsuya Ioka et al. JOURNAL OF CLINICAL ONCOLOGY
- The immune milieu of cholangiocarcinoma: From molecular pathogenesis to precision medicine
- (2019) Lorenza Rimassa et al. JOURNAL OF AUTOIMMUNITY
- Capecitabine plus oxaliplatin versus gemcitabine plus oxaliplatin as first-line therapy for advanced biliary tract cancers: a multicenter, open-label, randomized, phase III, noninferiority trial
- (2019) S T Kim et al. ANNALS OF ONCOLOGY
- The Intersection between Tumor Angiogenesis and Immune Suppression
- (2019) Osama E. Rahma et al. CLINICAL CANCER RESEARCH
- Updated results of a phase IIa study to evaluate the clinical efficacy and safety of erdafitinib in Asian advanced cholangiocarcinoma (CCA) patients with FGFR alterations.
- (2019) Joon Oh Park et al. JOURNAL OF CLINICAL ONCOLOGY
- A multi-center phase Ib/II study of nal-irinotecan, 5-fluouracil and leucovorin in combination with nivolumab as second-line therapy for patients with advanced unresectable biliary tract cancer.
- (2019) Vaibhav Sahai et al. JOURNAL OF CLINICAL ONCOLOGY
- Gemcitabine, Cisplatin, and nab-Paclitaxel for the Treatment of Advanced Biliary Tract Cancers
- (2019) Rachna T. Shroff et al. JAMA Oncology
- Nivolumab alone or in combination with cisplatin plus gemcitabine in Japanese patients with unresectable or recurrent biliary tract cancer: a non-randomised, multicentre, open-label, phase 1 study
- (2019) Makoto Ueno et al. Lancet Gastroenterology & Hepatology
- Combination gemcitabine plus S-1 versus gemcitabine plus cisplatin for advanced/recurrent biliary tract cancer: the FUGA-BT (JCOG1113) randomized phase III clinical trial
- (2019) C Morizane et al. ANNALS OF ONCOLOGY
- Therapeutic relevance of targeted sequencing in management of patients with advanced biliary tract cancer: DNA damage repair gene mutations as a predictive biomarker
- (2019) Heejung Chae et al. EUROPEAN JOURNAL OF CANCER
- Modified gemcitabine and oxaliplatin or gemcitabine + cisplatin in unresectable gallbladder cancer: Results of a phase III randomised controlled trial
- (2019) Atul Sharma et al. EUROPEAN JOURNAL OF CANCER
- Identification of four immune subtypes characterized by distinct composition and functions of tumor microenvironment in intrahepatic cholangiocarcinoma
- (2019) Sylvie Job et al. HEPATOLOGY
- Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1–2 trials
- (2019) Robert C Doebele et al. LANCET ONCOLOGY
- Phase II study of everolimus (RAD001) monotherapy as first-line treatment in advanced biliary tract cancer with biomarker exploration: the RADiChol Study
- (2018) David K. Lau et al. BRITISH JOURNAL OF CANCER
- In VivoStudy of Natural Killer (NK) Cell Cytotoxicity Against Cholangiocarcinoma in a Nude Mouse Model
- (2018) IN HYE JUNG et al. IN VIVO
- Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children
- (2018) Alexander Drilon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ramucirumab Plus Pembrolizumab in Patients with Previously Treated Advanced or Metastatic Biliary Tract Cancer: Nonrandomized, Open‐Label, Phase I Trial (JVDF)
- (2018) Hendrik‐Tobias Arkenau et al. ONCOLOGIST
- Nab-Paclitaxel and Gemcitabine as First-line Treatment of Advanced or Metastatic Cholangiocarcinoma
- (2018) Vaibhav Sahai et al. JAMA Oncology
- 615ORandomized phase III study of gemcitabine, cisplatin plus S-1 (GCS) versus gemcitabine, cisplatin (GC) for advanced biliary tract cancer (KHBO1401-MITSUBA)
- (2018) D Sakai et al. ANNALS OF ONCOLOGY
- Emerging Role of Combination Immunotherapy in the First-line Treatment of Advanced Renal Cell Carcinoma
- (2018) Saby George et al. JAMA Oncology
- Targeting Angiogenesis in Biliary Tract Cancers: An Open Option
- (2017) Valeria Simone et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
- (2017) Jedd D. Wolchok et al. NEW ENGLAND JOURNAL OF MEDICINE
- Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
- (2017) Dung T. Le et al. SCIENCE
- PD-L1 and PD-1 expression correlate with prognosis in extrahepatic cholangiocarcinoma
- (2017) Ke Ma et al. Oncology Letters
- PD-L1 expression in perihilar and intrahepatic cholangiocarcinoma
- (2017) Jacqueline Fontugne et al. Oncotarget
- Phase I study of chimeric antigen receptor modified T cells in treating HER2-positive advanced biliary tract cancers and pancreatic cancers
- (2017) Kaichao Feng et al. Protein & Cell
- Epi-drugs in combination with immunotherapy: a new avenue to improve anticancer efficacy
- (2017) Roberta Mazzone et al. Clinical Epigenetics
- Program Death 1 Immune Checkpoint and Tumor Microenvironment: Implications for Patients With Intrahepatic Cholangiocarcinoma
- (2016) Faiz Gani et al. ANNALS OF SURGICAL ONCOLOGY
- A Chimeric Switch-Receptor Targeting PD1 Augments the Efficacy of Second-Generation CAR T Cells in Advanced Solid Tumors
- (2016) Xiaojun Liu et al. CANCER RESEARCH
- Cholangiocarcinoma Heterogeneity Revealed by Multigene Mutational Profiling: Clinical and Prognostic Relevance in Surgically Resected Patients
- (2015) Andrea Ruzzenente et al. ANNALS OF SURGICAL ONCOLOGY
- Immunological Effects of Conventional Chemotherapy and Targeted Anticancer Agents
- (2015) Lorenzo Galluzzi et al. CANCER CELL
- PD-L1 and HLA Class I Antigen Expression and Clinical Course of the Disease in Intrahepatic Cholangiocarcinoma
- (2015) F. Sabbatino et al. CLINICAL CANCER RESEARCH
- Cediranib or placebo in combination with cisplatin and gemcitabine chemotherapy for patients with advanced biliary tract cancer (ABC-03): a randomised phase 2 trial
- (2015) Juan W Valle et al. LANCET ONCOLOGY
- Genomic spectra of biliary tract cancer
- (2015) Hiromi Nakamura et al. NATURE GENETICS
- Results of an abbreviated phase-II study with the Akt Inhibitor MK-2206 in Patients with Advanced Biliary Cancer
- (2015) Daniel H. Ahn et al. Scientific Reports
- The Interplay of Immunotherapy and Chemotherapy: Harnessing Potential Synergies
- (2015) Leisha A. Emens et al. Cancer Immunology Research
- Second-line chemotherapy in advanced biliary cancer: a systematic review
- (2014) A. Lamarca et al. ANNALS OF ONCOLOGY
- Activity and safety of RAD001 (everolimus) in patients affected by biliary tract cancer progressing after prior chemotherapy: a phase II ITMO study
- (2014) R. Buzzoni et al. ANNALS OF ONCOLOGY
- Phase II study of gemcitabine, oxaliplatin in combination with panitumumab in KRAS wild-type unresectable or metastatic biliary tract and gallbladder cancer
- (2014) A F Hezel et al. BRITISH JOURNAL OF CANCER
- Phase I dose-escalation and -expansion study of buparlisib (BKM120), an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors
- (2014) Jordi Rodon et al. INVESTIGATIONAL NEW DRUGS
- Cholangiocarcinoma
- (2014) Nataliya Razumilava et al. LANCET
- Gemcitabine and oxaliplatin with or without cetuximab in advanced biliary-tract cancer (BINGO): a randomised, open-label, non-comparative phase 2 trial
- (2014) David Malka et al. LANCET ONCOLOGY
- Mechanism of tumor rejection with doublets of CTLA-4, PD-1/PD-L1, or IDO blockade involves restored IL-2 production and proliferation of CD8+ T cells directly within the tumor microenvironment
- (2014) Stefani Spranger et al. Journal for ImmunoTherapy of Cancer
- Prognostic impact of tumour-infiltrating immune cells on biliary tract cancer
- (2013) B Goeppert et al. BRITISH JOURNAL OF CANCER
- Dendritic Cell-Based Immunotherapy Targeting Synthesized Peptides for Advanced Biliary Tract Cancer
- (2013) Masanori Kobayashi et al. JOURNAL OF GASTROINTESTINAL SURGERY
- Therapeutic Effects of Deleting Cancer-Associated Fibroblasts in Cholangiocarcinoma
- (2012) J. C. Mertens et al. CANCER RESEARCH
- Risk factors for cholangiocarcinoma
- (2011) Gia L. Tyson et al. HEPATOLOGY
- Frequent Mutation of Isocitrate Dehydrogenase (IDH)1 and IDH2 in Cholangiocarcinoma Identified Through Broad-Based Tumor Genotyping
- (2011) D. R. Borger et al. ONCOLOGIST
- Survey of Tyrosine Kinase Signaling Reveals ROS Kinase Fusions in Human Cholangiocarcinoma
- (2011) Ting-Lei Gu et al. PLoS One
- Gemcitabine alone or in combination with cisplatin in patients with biliary tract cancer: a comparative multicentre study in Japan
- (2010) T Okusaka et al. BRITISH JOURNAL OF CANCER
- Comparison of the pharmacokinetics and pharmacodynamics of S-1 between Caucasian and East Asian patients
- (2010) Benjamin Chuah et al. CANCER SCIENCE
- Phase 1 Trial of Wilms Tumor 1 (WT1) Peptide Vaccine and Gemcitabine Combination Therapy in Patients With Advanced Pancreatic or Biliary Tract Cancer
- (2010) Miho Kaida et al. JOURNAL OF IMMUNOTHERAPY
- Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer
- (2010) Juan Valle et al. NEW ENGLAND JOURNAL OF MEDICINE
- Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer
- (2010) Philip W. Kantoff et al. NEW ENGLAND JOURNAL OF MEDICINE
- PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors
- (2010) M. A. Curran et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Sorafenib in patients with advanced biliary tract carcinoma: a phase II trial
- (2009) C Bengala et al. BRITISH JOURNAL OF CANCER
- Efficacy and safety of gemcitabine, oxaliplatin, and bevacizumab in advanced biliary-tract cancers and correlation of changes in 18-fluorodeoxyglucose PET with clinical outcome: a phase 2 study
- (2009) Andrew X Zhu et al. LANCET ONCOLOGY
- Alpha-smooth muscle actin-positive fibroblasts promote biliary cell proliferation and correlate with poor survival in cholangiocarcinoma
- (2009) Thuwajit ONCOLOGY REPORTS
- Gemcitabine and oxaliplatin in advanced biliary tract carcinoma: a phase II study
- (2008) T André et al. BRITISH JOURNAL OF CANCER
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started